BN 80245

Drug Profile

BN 80245

Latest Information Update: 14 Dec 2001

Price : $50

At a glance

  • Originator Ipsen; Ipsen Pharma SA
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors; DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Dec 2001 Discontinued-Preclinical for Cancer in Europe (Unknown route)
  • 04 Jul 2000 Lasa Laboratories is now called Ipsen Pharma
  • 21 Jan 1999 Preclinical development for Cancer in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top